Wuhan Hiteck Biological Pharma Co.,Ltd (SHE:300683)
China · Delayed Price · Currency is CNY 35.25
-0.05 (-0.14%)
Apr 29, 2026, 3:04 PM CST
SHE:300683 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 543.82 | 541.45 | 645.7 | 594.48 | 680.74 | 608.2 |
Other Revenue | - | - | 3.27 | 7.8 | 7.89 | 6.49 |
| 543.82 | 541.45 | 648.97 | 602.28 | 688.63 | 614.68 | |
Revenue Growth (YoY) | -19.29% | -16.57% | 7.75% | -12.54% | 12.03% | 17.28% |
Cost of Revenue | 321.3 | 310.57 | 380.88 | 369.73 | 358.87 | 264.86 |
Gross Profit | 222.52 | 230.88 | 268.09 | 232.56 | 329.75 | 349.82 |
Selling, General & Admin | 273.04 | 271.25 | 245.86 | 241.99 | 220.52 | 242.96 |
Research & Development | 80.65 | 88.24 | 121.75 | 128.9 | 121.43 | 103.17 |
Other Operating Expenses | -7.14 | -6.84 | 7.11 | 5.44 | 5.64 | 3.51 |
Operating Expenses | 346.55 | 352.65 | 384.17 | 372.1 | 363.44 | 363.02 |
Operating Income | -124.03 | -121.77 | -116.08 | -139.54 | -33.69 | -13.2 |
Interest Expense | - | - | -2.3 | -2.39 | -1.12 | -0.5 |
Interest & Investment Income | 20.24 | 20.64 | 24.84 | 25.68 | 23.9 | 27.94 |
Other Non Operating Income (Expenses) | -0.39 | -1.44 | -0.71 | -0.46 | -0.49 | -0.56 |
EBT Excluding Unusual Items | -104.18 | -102.56 | -94.24 | -116.71 | -11.4 | 13.68 |
Impairment of Goodwill | - | - | - | -38.56 | -14.02 | - |
Gain (Loss) on Sale of Investments | -14.12 | -12.52 | -10.22 | 1.9 | 12.67 | -0.33 |
Gain (Loss) on Sale of Assets | -3.12 | -0.98 | -0.07 | -0.36 | -0.09 | -0.18 |
Asset Writedown | -128.36 | -122.7 | -1.15 | -4.03 | -0.06 | -0.02 |
Other Unusual Items | - | - | 25.54 | 5.78 | 5.07 | 7.31 |
Pretax Income | -249.77 | -238.76 | -80.14 | -151.99 | -7.82 | 20.46 |
Income Tax Expense | -4.83 | -3.33 | -6.37 | -23.74 | 0.07 | -9.56 |
Earnings From Continuing Operations | -244.95 | -235.43 | -73.77 | -128.24 | -7.9 | 30.01 |
Minority Interest in Earnings | 4.56 | 4.16 | 4.42 | 7.42 | -6.13 | -2.36 |
Net Income | -240.38 | -231.27 | -69.35 | -120.82 | -14.03 | 27.65 |
Net Income to Common | -240.38 | -231.27 | -69.35 | -120.82 | -14.03 | 27.65 |
Shares Outstanding (Basic) | 131 | 131 | 131 | 130 | 128 | 106 |
Shares Outstanding (Diluted) | 131 | 131 | 131 | 130 | 128 | 106 |
Shares Change (YoY) | 0.24% | -0.14% | 0.71% | 1.86% | 19.91% | 2.00% |
EPS (Basic) | -1.83 | -1.77 | -0.53 | -0.93 | -0.11 | 0.26 |
EPS (Diluted) | -1.83 | -1.77 | -0.53 | -0.93 | -0.11 | 0.26 |
Free Cash Flow | -78.25 | -127.07 | -20.39 | -162.13 | -120.94 | -235.02 |
Free Cash Flow Per Share | -0.60 | -0.97 | -0.16 | -1.25 | -0.95 | -2.21 |
Dividend Per Share | - | - | 0.130 | - | - | - |
Gross Margin | 40.92% | 42.64% | 41.31% | 38.61% | 47.88% | 56.91% |
Operating Margin | -22.81% | -22.49% | -17.89% | -23.17% | -4.89% | -2.15% |
Profit Margin | -44.20% | -42.71% | -10.69% | -20.06% | -2.04% | 4.50% |
Free Cash Flow Margin | -14.39% | -23.47% | -3.14% | -26.92% | -17.56% | -38.23% |
EBITDA | -28.54 | -28 | -29.2 | -70.85 | 17.5 | 22.42 |
EBITDA Margin | -5.25% | -5.17% | -4.50% | -11.76% | 2.54% | 3.65% |
D&A For EBITDA | 95.49 | 93.77 | 86.88 | 68.69 | 51.18 | 35.62 |
EBIT | -124.03 | -121.77 | -116.08 | -139.54 | -33.69 | -13.2 |
EBIT Margin | -22.81% | -22.49% | -17.89% | -23.17% | -4.89% | -2.15% |
Revenue as Reported | - | - | 648.97 | 602.28 | 688.63 | 614.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.